Request Free Sample ×
ReportInfographic

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

South America Benign Prostatic Hyperplasia Treatment Market

ID: MRFR/MED/49922-HCR
200 Pages
Nidhi Mandole
Last Updated: February 06, 2026

South America Benign Prostatic Hyperplasia Treatment Market Research Report By Therapeutic Class (Alpha Blockers, 5- Alpha Reductase Inhibitors, Phosphodiesterase-5 Inhibitors, Others), By Therapy (Mono Drug Therapy, Combination Drug Therapy) and By Regional (Brazil, Mexico, Argentina, Rest of South America) - Growth & Industry Forecast 2025 To 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

South America Benign Prostatic Hyperplasia Treatment Market Infographic
Purchase Options
Compare License
Summary Table of Contents Segmentation Download PDF
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
  2.   1.1 EXECUTIVE SUMMARY
  3.     1.1.1 Market Overview
  4.     1.1.2 Key Findings
  5.     1.1.3 Market Segmentation
  6.     1.1.4 Competitive Landscape
  7.     1.1.5 Challenges and Opportunities
  8.     1.1.6 Future Outlook
  9. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
  10.   2.1 MARKET INTRODUCTION
  11.     2.1.1 Definition
  12.     2.1.2 Scope of the study
  13.       2.1.2.1 Research Objective
  14.       2.1.2.2 Assumption
  15.       2.1.2.3 Limitations
  16.   2.2 RESEARCH METHODOLOGY
  17.     2.2.1 Overview
  18.     2.2.2 Data Mining
  19.     2.2.3 Secondary Research
  20.     2.2.4 Primary Research
  21.       2.2.4.1 Primary Interviews and Information Gathering Process
  22.       2.2.4.2 Breakdown of Primary Respondents
  23.     2.2.5 Forecasting Model
  24.     2.2.6 Market Size Estimation
  25.       2.2.6.1 Bottom-Up Approach
  26.       2.2.6.2 Top-Down Approach
  27.     2.2.7 Data Triangulation
  28.     2.2.8 Validation
  29. 3 SECTION III: QUALITATIVE ANALYSIS
  30.   3.1 MARKET DYNAMICS
  31.     3.1.1 Overview
  32.     3.1.2 Drivers
  33.     3.1.3 Restraints
  34.     3.1.4 Opportunities
  35.   3.2 MARKET FACTOR ANALYSIS
  36.     3.2.1 Value chain Analysis
  37.     3.2.2 Porter's Five Forces Analysis
  38.       3.2.2.1 Bargaining Power of Suppliers
  39.       3.2.2.2 Bargaining Power of Buyers
  40.       3.2.2.3 Threat of New Entrants
  41.       3.2.2.4 Threat of Substitutes
  42.       3.2.2.5 Intensity of Rivalry
  43.     3.2.3 COVID-19 Impact Analysis
  44.       3.2.3.1 Market Impact Analysis
  45.       3.2.3.2 Regional Impact
  46.       3.2.3.3 Opportunity and Threat Analysis
  47. 4 SECTION IV: QUANTITATIVE ANALYSIS
  48.   4.1 Construction, BY Therapeutic Class (USD Million)
  49.     4.1.1 Alpha Blockers
  50.     4.1.2 5- Alpha Reductase Inhibitors
  51.     4.1.3 Phosphodiesterase-5 Inhibitors
  52.     4.1.4 Others
  53.   4.2 Construction, BY Therapy (USD Million)
  54.     4.2.1 Mono Drug Therapy
  55.     4.2.2 Combination Drug Therapy
  56. 5 SECTION V: COMPETITIVE ANALYSIS
  57.   5.1 Competitive Landscape
  58.     5.1.1 Overview
  59.     5.1.2 Competitive Analysis
  60.     5.1.3 Market share Analysis
  61.     5.1.4 Major Growth Strategy in the Construction
  62.     5.1.5 Competitive Benchmarking
  63.     5.1.6 Leading Players in Terms of Number of Developments in the Construction
  64.     5.1.7 Key developments and growth strategies
  65.       5.1.7.1 New Product Launch/Service Deployment
  66.       5.1.7.2 Merger & Acquisitions
  67.       5.1.7.3 Joint Ventures
  68.     5.1.8 Major Players Financial Matrix
  69.       5.1.8.1 Sales and Operating Income
  70.       5.1.8.2 Major Players R&D Expenditure. 2023
  71.   5.2 Company Profiles
  72.     5.2.1 Astellas Pharma (JP)
  73.       5.2.1.1 Financial Overview
  74.       5.2.1.2 Products Offered
  75.       5.2.1.3 Key Developments
  76.       5.2.1.4 SWOT Analysis
  77.       5.2.1.5 Key Strategies
  78.     5.2.2 Boehringer Ingelheim (DE)
  79.       5.2.2.1 Financial Overview
  80.       5.2.2.2 Products Offered
  81.       5.2.2.3 Key Developments
  82.       5.2.2.4 SWOT Analysis
  83.       5.2.2.5 Key Strategies
  84.     5.2.3 Eli Lilly and Company (US)
  85.       5.2.3.1 Financial Overview
  86.       5.2.3.2 Products Offered
  87.       5.2.3.3 Key Developments
  88.       5.2.3.4 SWOT Analysis
  89.       5.2.3.5 Key Strategies
  90.     5.2.4 GlaxoSmithKline (GB)
  91.       5.2.4.1 Financial Overview
  92.       5.2.4.2 Products Offered
  93.       5.2.4.3 Key Developments
  94.       5.2.4.4 SWOT Analysis
  95.       5.2.4.5 Key Strategies
  96.     5.2.5 Johnson & Johnson (US)
  97.       5.2.5.1 Financial Overview
  98.       5.2.5.2 Products Offered
  99.       5.2.5.3 Key Developments
  100.       5.2.5.4 SWOT Analysis
  101.       5.2.5.5 Key Strategies
  102.     5.2.6 Merck & Co. (US)
  103.       5.2.6.1 Financial Overview
  104.       5.2.6.2 Products Offered
  105.       5.2.6.3 Key Developments
  106.       5.2.6.4 SWOT Analysis
  107.       5.2.6.5 Key Strategies
  108.     5.2.7 Pfizer (US)
  109.       5.2.7.1 Financial Overview
  110.       5.2.7.2 Products Offered
  111.       5.2.7.3 Key Developments
  112.       5.2.7.4 SWOT Analysis
  113.       5.2.7.5 Key Strategies
  114.     5.2.8 Sanofi (FR)
  115.       5.2.8.1 Financial Overview
  116.       5.2.8.2 Products Offered
  117.       5.2.8.3 Key Developments
  118.       5.2.8.4 SWOT Analysis
  119.       5.2.8.5 Key Strategies
  120.     5.2.9 Teva Pharmaceutical Industries (IL)
  121.       5.2.9.1 Financial Overview
  122.       5.2.9.2 Products Offered
  123.       5.2.9.3 Key Developments
  124.       5.2.9.4 SWOT Analysis
  125.       5.2.9.5 Key Strategies
  126.   5.3 Appendix
  127.     5.3.1 References
  128.     5.3.2 Related Reports
  129. 6 LIST OF FIGURES
  130.   6.1 MARKET SYNOPSIS
  131.   6.2 SOUTH AMERICA MARKET ANALYSIS BY THERAPEUTIC CLASS
  132.   6.3 SOUTH AMERICA MARKET ANALYSIS BY THERAPY
  133.   6.4 KEY BUYING CRITERIA OF CONSTRUCTION
  134.   6.5 RESEARCH PROCESS OF MRFR
  135.   6.6 DRO ANALYSIS OF CONSTRUCTION
  136.   6.7 DRIVERS IMPACT ANALYSIS: CONSTRUCTION
  137.   6.8 RESTRAINTS IMPACT ANALYSIS: CONSTRUCTION
  138.   6.9 SUPPLY / VALUE CHAIN: CONSTRUCTION
  139.   6.10 CONSTRUCTION, BY THERAPEUTIC CLASS, 2024 (% SHARE)
  140.   6.11 CONSTRUCTION, BY THERAPEUTIC CLASS, 2024 TO 2035 (USD Million)
  141.   6.12 CONSTRUCTION, BY THERAPY, 2024 (% SHARE)
  142.   6.13 CONSTRUCTION, BY THERAPY, 2024 TO 2035 (USD Million)
  143.   6.14 BENCHMARKING OF MAJOR COMPETITORS
  144. 7 LIST OF TABLES
  145.   7.1 LIST OF ASSUMPTIONS
  146.     7.1.1
  147.   7.2 South America MARKET SIZE ESTIMATES; FORECAST
  148.     7.2.1 BY THERAPEUTIC CLASS, 2025-2035 (USD Million)
  149.     7.2.2 BY THERAPY, 2025-2035 (USD Million)
  150.   7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  151.     7.3.1
  152.   7.4 ACQUISITION/PARTNERSHIP
  153.     7.4.1

South America Construction Market Segmentation

Construction By Therapeutic Class (USD Million, 2025-2035)

  • Alpha Blockers
  • 5- Alpha Reductase Inhibitors
  • Phosphodiesterase-5 Inhibitors
  • Others

Construction By Therapy (USD Million, 2025-2035)

  • Mono Drug Therapy
  • Combination Drug Therapy

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories
Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization ✓ ✓ ✓
Direct Access to Analyst ✓ ✓ ✓
Deliverable Format ✓ ✓ ✓
Platform Access ✗ ✗ ✓
Discount on Next Purchase 10% 15% 15%
Printable Versions ✗ ✗ ✓